GautamGopaljiJhaMD

Oncology • Minneapolis, MN

Assistant Professor, Medicine, University of Minnesota Medical School, Minneapolis

Join to view full profile

Dr. Jha is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Jha's full profile

Already have an account?

Office
909 Fulton Street, Masonic Cancer Center
Masonic Cancer Center, Division of Hematology, Oncology and Transplant (Dept Of Medicine)
Minneapolis, MN 55455
Phone+1 612-676-4200

Education & Training

University of MinnesotaFellowship, Hematology and Medical Oncology, 2007 - 2010
University of TennesseeResidency, Internal Medicine, 2005 - 2007
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalInternship, Internal Medicine, 2004 - 2005
Terna Medical CollegeClass of 1998

Certifications & Licensure

MN State Medical License 2007 - 2025
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Everolimus Versus Placebo in Head and Neck Cancer Start of enrollment: 2010 Apr 01
Terminated
Phase 2
Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity Start of enrollment: 2010 Dec 01
Completed
Phase 3
Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer Start of enrollment: 2012 Oct 01
Completed
Phase 2
Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer Start of enrollment: 2012 Jun 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274.
Matthew D Galsky, Johannes Alfred Witjes, Jürgen E Gschwend, Matthew I Milowsky, Michael Schenker
Journal of Clinical Oncology. 2024-10-11
Clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with abiraterone with or without ongoing androgen deprivation therapy: A retro...
Ali T Arafa, Leah R Blader, Karan Ramakrishna, Jeff Engle, Charles J Ryan
The Prostate. 2023-09-01
6 citations
A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck.
Cherie-Ann O Nathan, D Neil Hayes, Theodore Karrison, Olivier Harismendy, José M Flores
Clinical Cancer Research. 2022-12-01

Lectures

Suppression of testosterone production using abiraterone acetate (AA) with or without androgen deprivation therapy (ADT) in metastatic castration resistant prostate ca...
2019 ASCO Annual Meeting - 6/1/2019

Professional Memberships

American Society of Clinical Oncology - ASCO
Member